Biomedical research has led to profound advances in the treatment of HIV infection. Combination antiretroviral therapy (ART) now provides the means to readily control viral infection, and people living with HIV who receive timely and effective ART can expect to benefit from a life expectancy comparable to uninfected individuals. Nevertheless, despite effective treatment, ART does not fully restore the immune system and importantly HIV persists indefinitely in latent reservoirs, resulting in the need for life-long treatment. The challenges and limits of life-long treatment have spurred significant scientific interest and global investment into research towards an HIV cure. The International AIDS Society (IAS) 2014 Towards an HIV cure symposium brought together researchers and community to discuss the most recent advances in our understanding of latency and HIV reservoirs, and the clinical approaches towards an HIV cure under current investigation. This report summarizes and reviews some of the major findings discussed during the symposium.
Get full access to this article
View all access options for this article.
References
1.
HenrichTJ, HanhauserE, MartyFM, et al.: Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: Report of 2 cases. Ann Intern Med, 2014; 161(5):319–327.
2.
HenrichTJ, HuZ, LiJZ, et al.: Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis, 2013; 207(11):1694–1702.
3.
FennesseyCR and KeeleB: Ultra-deep barcoded SIVmac259 to identify and quantify viral reservoirs and recrudescent viremia. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
4.
HechtFM and PalmerS: Genetically characterizing the role of cell proliferation in maintaining persistent HIV during effective HIV therapy. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
5.
FromentinR, BakemanW, LawaniMB, et al.: The immune checkpoint blockers PD-1, LAG-3 and TIGIT are biomarkers of HIV infected cells during ART and identify distinct cellular reservoirs. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
6.
EvansVA, KumarN, FilaliA, et al.: Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells. PLoS Pathog, 2013; 9(12):e1003799.
7.
EvansVA, van der SluisRM, KumarNA, et al.: Following in vitro culture with myeloid dendritic cells, negative regulators of T-cell activation are expressed preferentially on latently infected CD4+ T-cells. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
8.
International ASSWGoHIVC, DeeksSG, AutranB, et al.: Towards an HIV cure: A global scientific strategy. Nat Rev Immunol, 2012; 12(8):607–614.
9.
HoYC, ShanL, HosmaneNN, et al.: Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell, 2013; 155(3):540–551.
10.
ProcopioFA, FromentinR, KulpaD, et al.: A novel assay that precisely measures the size of the latent HIV reservoir reveal that ART-naive individuals harbour a large pool of latently infected CD4+ T-cells. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
11.
WhitneyJB, HillAL, SanisettyS, et al.: Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature, 2014; 512(7512):74–77.
12.
RouziouxC: Impact of antiretroviral treatment on HIV reservoirs. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
13.
DeeksSG: HIV: Shock and kill. Nature, 2012; 487(7408):439–440.
14.
WightmanF, EllenbergP, ChurchillM, and LewinSR: HDAC inhibitors in HIV. Immunol Cell Biol, 2012; 90(1):47–54.
15.
SpinaCA, AndersonJ, ArchinNM, et al.: An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog, 2013; 9(12):e1003834.
16.
TolstrupM, ViganoS, OlesenR, et al.: Immunological correlates of HIV-1 DNA decline during latency reversal with panobinostat in patients on suppressive cART. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
17.
RasmussenTA, TolstrupM, BrinkmannCR, et al.: Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: A phase 1/2, single group, clinical trial. Lancet HIV, 2014; 1(1):e13–e21.
18.
SøgaardOS, GraversenME, LethS, et al.: The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
19.
WeiDG, ChiangV, FyneE, et al.: Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog, 2014; 10(4):e1004071.
20.
WightmanF, ElliotJH, SolomonAE, et al.: Multidose vorinostat in HIV-infected individuals on effective ART leads to an increase in regulatory T-cells but no change in inducible virus or HIV-specific T-cells. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
21.
DarcisG, KulaA, BouchatK, et al.: Synergistic activation of HIV-1 expression by compounds releasing active positive transcription elongation factor b (P-TEFb) and by inducers of the NF-kB signaling pathway. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
22.
AbreuCM, PriceSL, ShirkEN, et al.: Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: Inhibition of de novo infection and activation of viral LTR. PLoS One, 2014; 9(5):e97257.
23.
JiangG, MendesEA, KaiserP, et al.: Reactivation of HIV latency by a newly modified ingenol derivative via protein kinase Cdelta-NF-kappaB signaling. AIDS, 2014; 28(11):1555–1566.
24.
BoehmD, CalvaneseV, DarRD, et al.: BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle, 2013; 12(3):452–462.
25.
BanerjeeC, ArchinN, MichaelsD, et al.: BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol, 2012; 92(6):1147–1154.
26.
ChomontN, El-FarM, AncutaP, et al.: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med, 2009; 15(8):893–900.
27.
BosqueA, NovisC, MartinsL, et al.: A new family of compounds that reactivate latent HIV in central memory T cells. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
28.
SelliahN, ZhangM, DeSimoneD, et al.: The gammac-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells. Virology, 2006; 344(2):283–291.
29.
CartaA, PalombaM, BoattoG, et al.: Synthesis and antiproliferative activity of 3-aryl-2-[1H(2H)-benzotriazol-1(2)-yl]acrylonitriles variously substituted: Part 4. Farmaco, 2004; 59(8):637–644.
30.
ArchinNM, LibertyAL, KashubaAD, et al.: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012; 487(7408):482–485.
31.
SpivakAM, AndradeA, EiseleE, et al.: A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis, 2014; 58(6):883–890.
32.
ElliottJAS: the safety and effect of multiple doses of vorinostat on HIV transcription in HIV+ patients receiving cART. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia, 2013.
33.
ArchinNM, BatesonR, TripathyMK, et al.: HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis, 2014; 210(5):728–735.
34.
RasmussenT: Panobinostat induces HIV transcription and plasma viremia in HIV patients on suppressive cART. Conference on Retroviruses and Opportunistic Infections, 2014.
35.
Zolla-PaznerS: A critical question for HIV vaccine development: Which antibodies to induce?. Science, 2014; 345(6193):167–168.
36.
WalkerLM, HuberM, DooresKJ, et al.: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature, 2011; 477(7365):466–470.
37.
BarouchDH: Therapeutic efficacy of neutralizing antibodies for HIV. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
38.
WuX, YangZY, LiY, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science, 2010; 329(5993):856–861.
39.
ZhouT, GeorgievI, WuX, et al.: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science, 2010; 329(5993):811–817.
40.
PeguA, YangZY, BoyingtonJC, et al.: Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med, 2014; 6(243):243ra288.
41.
SuB, LederleA, SchmidtS, et al.: Potent and broadly anti-HIV-1 neutralizing antibody VRC01 inhibits HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
42.
BarouchDH and DeeksSG: Immunologic strategies for HIV-1 remission and eradication. Science, 2014; 345(6193):169–174.
43.
PetrovasC, Ferrando-MartinezS, PeguA, et al.: A population of CD8 T cells is located in the germinal centers that is functionally capable of mediating bi-specific antibody mediated killing of HIV-infected T-cells. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
44.
MylvaganamG, VeluV, and AmaraRR: Co-localization of follicular SIV-specific CD8 T-cells with Tfh in the germinal centers of chronically SIV infected Rhesus macaques is associated with enhanced viral control. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
45.
MargolisD, GarridoC, SungJM, et al.: Induction and clearance of latent HIV infection: Modeling viral clearance by immune effectors using cells from ART-treated patients. 2014 IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
46.
LeenAM, MyersGD, SiliU, et al.: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med, 2006; 12(10):1160–1166.
47.
BollardCM, GottschalkS, LeenAM, et al.: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood, 2007; 110(8):2838–2845.
48.
MarrasF, BozzanoF, AsciertoML, and De MariaA: Baseline and dynamic expression of activating NK cell receptors in the control of chronic viral infections: The paradigm of HIV-1 and HCV. Front Immunol., 2014; 5:305.
49.
HansenSG, PiatakMJr, VenturaAB, et al.: Immune clearance of highly pathogenic SIV infection. Nature, 2013; 502(7469):100–104.
50.
LifsonJ: The role of therapeutic vaccination in HIV cure strategies. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
51.
FauciAS: Critical challenges in HIV discovery: Cure and vaccine. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
52.
OttM: Epigenetic regulation of HIV latency. 2014IAS Towards an HIV cure symposium. Melbourne, Australia, 2014.
53.
TAG: Research Toward a Cure Trials. www.treatmentactiongroup.org/cure/trials, 2014.
54.
PersaudD, GayH, ZiemniakC, et al.: Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med, 2013; 369(19):1828–1835.
55.
Saez-CirionA, BacchusC, HocquelouxL, et al.: Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy: ANRS VISCONTI Study. PLoS Pathog, 2013; 9(3):e1003211.
56.
FauciAS, MarstonHD, and FolkersGK: An HIV cure: Feasibility, discovery, and implementation. JAMA, 2014; 312(4):335–336.
